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     Obesity poses a serious health hazard and contributes to the increase morbidity and mortality since 
it increases an individual’s risk to comorbidities like type 2 diabetes, cardiovascular diseases, certain 
cancers and other related life-style diseases. Obesity is characterized by a state of positive energy balance 
leading to increase in adipose tissue mass. Adipose tissue mass increase relates to the changes in the size 
or number of adipocytes. Adipose tissue mass can increase in two ways: hyperplasia, which is 
characterized by an increase in the cell number or hypertrophy, which is brought about by an increase in 
the size of the cell. The adipocytes- a capricious cell that has evolved to provide mammalian energy 
storage- regulates itself depending on the environment. Obesity includes the changes in the functions of 
adipocytes, such as the onset of insulin resistance, adipocyte inflammation, and the associated metabolic 
syndrome. One of the earliest events in the adipocyte differentiation is the activation of the peroxisome 
proliferator-activated receptor (PPAR)γ as a master regulator of adipogenesis. Since PPARγ is a 
ligand-activated transcription factor, endogenous ligands should be provided for the activation of PPARγ 
in adipose tissues. The present study was undertaken to conduct health science studies on the novel roles 
of bioactive lipids and lipid parameters in adipogenesis, adipocyte inflammation, and metabolic 
syndrome. 
     The biochemical and molecular biological studies clarified the regulation of gene expression of 
isoforms of cyclooxygenases (COXs) linked to the prostaglandin (PG)D syntheses at the levels of enzyme 
activities, proteins, and the transcription upon several external signals. PGD2 can be produced in 
adipocytes and dehydrated to PGs of J2 series including 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2) and Δ12-PGJ2, 
that are considered as pro-adipogenic prostanoids through the activation of PPARγ. Several lines of 
evidences suggested the generation of 15d-PGJ2 in matured adipocytes and its contribution to the 
upregulation of adipogenesis. However, the quantitative determination of Δ12-PGJ2 has not been 
attempted during the life stage of adipocytes. In this study, an enzyme-linked immunosorbent assay using 
mouse antiserum specific for Δ12-PGJ2 was developed. According to the standard curve, the amount of 
Δ12-PGJ2 can be measured from 0.5 pg to 14.4 ng in an assay. This antiserum did not recognize most other 
prostanoids including 15d-PGJ2, while it only showed the cross-reaction of 28% with unstable PGJ2. This 
immunological assay was applied to the determination of the endogenous formation of Δ12-PGJ2 in 
cultured 3T3-L1 adipocytes during the maturation phase. The ability of cultured adipocytes to form 
endogenous Δ12-PGJ2 increased gradually at an earlier stage of the maturation phase and detectable at 
higher levels than 15d-PGJ2. Treatment of cultured cells with either aspirin or indomethacin, a general 
cyclooxygenase inhibitor, significantly reduced the production of endogenous Δ12-PGJ2 in the maturation 
medium as expected. Furthermore, the exogenous effects of PGJ2 series were evaluated individually at 
various doses on adipogenesis during the maturation phase. Although Δ12-PGJ2 was slightly less potent 
than 15d-PGJ2, each of these PGJ2 series rescued effectively both the accumulation of fats and the gene 
expression of typical adipocyte-markers that were attenuated in the presence of aspirin. Taken together, 
these findings indicate that endogenous Δ12-PGJ2 contributes substantially to the up-regulation of 
adipogenesis program through the activation of PPARγ together with 15d-PGJ2 during the maturation 
phase of cultured adipocytes.  
     The role of lipocalin-type PGD synthase (L-PGDS) in adipocytes remains still uncertain due to the 
related enzymatic or non-enzymatic conversion of PGD2 as well as the multiple cell-surface membrane 
receptors and the nuclear receptors for PGD2 and PGJ2 series. Here, to study the role of L-PGDS in 
adipogenesis, the transfection technology was undertaken to manipulate the expression levels of 
intracellular L-PGDS in cultured preadipocytes. The resulting stable transfectants were employed to 
monitor adipogenesis associated with the sustained expression of L-PGDS in adipocytes during the 
maturation phase. To manipulate the expression levels of L-PGDS in cultured adipocytes, cultured 
preadipogenic 3T3-L1 cells were transfected stably with a mammalian expression vector having cDNA 
encoding murine L-PGDS oriented in the sense direction. The isolated cloned stable transfectants with 
L-PGDS expressed higher levels of the transcript and protein levels of L-PGDS, and synthesized PGD2 
from exogenous arachidonic acid at significantly higher levels. By contrast, the synthesis of PGE2 
remained unchanged, indicating no influence on the reactions of COX and PGE synthase. Furthermore, 
the ability of these transfectants to synthesize Δ12-PGJ2 increased more greatly during the maturation 
phase. The sustained expression of L-PGDS in cultured stable transfectants hampered the storage of fats 
during the maturation phase of adipocytes, which was accompanied by the reduced gene expression of 
adipocyte-specific markers reflecting the down-regulation of adipogenesis program. The suppressed 
adipogenesis was not rescued by either of exogenous aspirin and PPARγ agonists including troglitazone 
and 15d-PGJ2. Taken together, the results indicate the negative regulation of adipogenesis program by the 
enhanced expression of L-PGDS through a cellular mechanism involving the interference of the PPARγ 
signaling pathway without the contribution of endogenous pro-adipogenic prostanoids.  
     Alternatively, I investigated whether PGJ2 derivatives can modulate the gene expression of 
monocyte chemoattractant protein-1 (MCP-1), a pro-inflammatory chemokine, during the maturation 
phase of adipocytes. Each of selective or nonselective inhibitors for COX isoforms suppressed 
significantly the accumulation of fats by interfering the induced expression of the PPARγ gene. 
Immunological assays of PGJ2 series revealed higher production of Δ12-PGJ2 than 15d-PGJ2 by cultured 
adipocytes, implicating the contribution of endogenous PGJ2 series to the stimulated adipogenesis. In 
addition, the increased transcription of MCP-1 was detectable at later maturation phase of adipogeneis, 
which was prevented by co-incubation with aspirin. Although 15d-PGJ2 was more potent than Δ12-PGJ2, 
both PGJ2 series had similar effects to rescue dose-dependently the expression of the MCP-1 gene 
attenuated by aspirin. These findings suggest that the expression of MCP-1 involved in adipocyte 
inflammation could be positively regulated by those PGJ2 series during adipogenesis in adipose tissue. 
Our current studies should promote further attempts to understand the role of endogenous PGJ2 series in 
the regulation of the gene expression of pro-inflammatory factors in adipose tissue in vivo. 
     Diabetes mellitus is becoming a pandemic worldwide due to the global increase in obesity and 
sedentary lifestyles. Here, I aimed at to explore the prevalence of metabolic syndrome among persons of 
different age groups visiting to a diabetic clinic, and living in a coastal area of Bangladesh. Metabolic 
syndrome is a clustering of metabolic abnormalities that has close association with cardiovascular 
mortality. Metabolic syndrome has becoming a major challenge for public health. To get insight 
knowledge about the metabolic syndrome in diabetes, this population-based study was designed. Here I 
assessed the metabolic syndrome in diabetes from a coastal region of Bangladesh. Metabolic syndrome 
was estimated by using the modified definition of the National Cholesterol Education Program Adult 
Treatment Panel III. A total of 500 patients visiting to a diabetic clinic were included in this study. 
Anthropometric, clinical and biochemical data were recorded. Our result revealed that, about 47.0% 
patients with type 2 diabetic mellitus were suffering from metabolic syndrome. Female were more 
prevalent than male (58.6% vs 36.1%) for suffering from metabolic syndrome. Among other risk factors 
for metabolic syndrome, obesity and hypertriglyceridemia followed by low levels of high-density 
lipoprotein (HDL) were more prevalent in female. In contrast, male were more likely to have low levels 
of HDL and hypertriglyceridemia followed by high blood pressure. Since diabetic patients are more prone 
to suffer from metabolic syndrome, and it becomes a major risk factor for cardiovascular disease, correct 
measurement should be taken to identify metabolic syndrome among different population to reduce the 
high abnormalities. 
     Thus, in light of the roles played by PGJ2 metabolites and overexpressed L-PGDS in adipogenesis, 
the manipulation of lipid mediator signaling, through either enzyme manipulation or receptor antagonists 
and agonists, has potential as a therapeutic approach to the associated metabolic disease. Furthermore, the 
present study was able to provide the novel results on the facets regarding the roles for bioactive lipids in 
adipocyte inflammation, and clarified the specific lipid parameters associated with metabolic syndrome in 
diabetic patients in a coastal region of Bangladesh. 
